en · de · es · fr · pt
melanotan-2-notes.peptides5388.com › Info › Background And Mechanism Of Melanotan-2 — Deep Dive

Background And Mechanism Of Melanotan-2 — Deep Dive

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-16 · Info

If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan-2 at a glance

PropertyValueNotes
Compound classSynthetic cyclic heptapeptideAlpha-MSH analogue containing a D-phenylalanine residue
Molecular formulaC50H69N15O9Average molecular mass approximately 1024.2 g/mol
AppearanceWhite to off-white lyophilised powderNormally supplied as a freeze-dried solid in a sealed vial
SolubilityFreely soluble in water and polar solventsDissolves readily in aqueous buffers and in alcohol-water mixtures
Receptor targetsMC1R, MC3R, MC4R, MC5RActs as a non-selective melanocortin receptor agonist

Origins and Research Status

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Related pages on this site

Reference notes

== Packaging == Frozen food packaging must maintain its integrity throughout filling, sealing, freezing, storage, transportation, thawing, and often cooking. As many frozen foods are cooked in a microwave oven, manufacturers have developed packaging that can go directly from freezer to the microwave. In 1974, the first differential heating container (DHC) was sold to the public. A DHC is a sleeve of metal designed to allow frozen foods to receive the correct amount of heat. Various sized apertures were positioned around the sleeve. The consumer would put the frozen dinner into the sleeve according to what needed the most heat. This ensured proper cooking. Today there are multiple options for packaging frozen foods. Boxes, cartons, bags, pouches, boil-in-bags, lidded trays and pans, crystallized PET trays, and composite and plastic cans. Scientists continue to research new aspects of frozen food packaging. Active packaging offers many new technologies that can actively sense and then neutralize the presence of bacteria or other harmful species. Active packaging can extend shelf-life, maintain product safety, and help preserve the food over a longer period of time. Several functions of active packaging are being researched:

== See also == Executive order List of executive actions by Barack Obama List of executive actions by Joe Biden List of executive orders in the second presidency of Donald Trump List of bills in the 119th United States Congress

For shelter, the Komodo dragon digs holes that can measure from 1 to 3 m (3.3 to 9.8 ft) wide with its powerful forelimbs and claws. Because of its large size and habit of sleeping in these burrows, it is able to conserve body heat throughout the night and minimise its basking period the morning after. The Komodo dragon stays in the shade during the hottest part of the day and hunts in the afternoon. These special resting places, usually located on ridges with cool sea breezes, are marked with droppings and are cleared of vegetation. They serve as strategic locations from which to ambush deer.

== Function == Nicotinamide phosphoribosyl­transferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.

Sources: en.wikipedia.org

Reference notes

continuously collect small fractions of the effluent from 1D, ensuring that the separation is maintained in this dimension; focus or refocus the effluent of a narrow band; to quickly transfer the 2D fraction collected and focused as a narrow pulse. Taken together, these three steps are called modulation cycle, which is repeated throughout the chromatographic run.

The kinase AKT indirectly promotes synthesis of rRNA as RNA polymerase I is AKT-dependent. Certain angiogenic ribonucleases, such as angiogenin (ANG), can translocate and accumulate in the nucleolus. When the concentration of ANG becomes too high, some studies have found that ANG can bind to the promoter region of rDNA and unnecessarily increase rRNA transcription. This can be damaging to the nucleolus and can even lead to unchecked transcription and cancer. During times of cellular glucose restriction, AMP-activated protein kinase (AMPK) discourages metabolic processes that consume energy but are non-essential. As a result, it is capable of phosphorylating RNA polymerase I (at the Ser-635 site) in order to down-regulate rRNA synthesis by disrupting transcription initiation. Impairment or removal of more than one pseudouridine or 29-O-methylation regions from the ribosome decoding center significantly reduces rate of rRNA transcription by reducing the rate of incorporation of new amino acids. Formation of heterochromatin is essential to silencing rRNA transcription, without which ribosomal RNA is synthesized unchecked and greatly decreases the lifespan of the organism.

== Career == In 1977, Bowman joined International Plasma Corporation of Hayward, California as chief financial officer and general manager of its analytical instrument division. International Plasma Corporation owned Durrum Instrument Corporation, an instrumentation company that had purchased exclusive rights to an emergent technology, Ion chromatography, from Dow Chemical Company. Initial research by Hamish Small and others at the Dow Physical Research Laboratory in Midland, Michigan suggested that inorganic ion analysis would be superior to commonly used wet chemical techniques, but Dow was not interested in pursuing the idea. Bowman became interested in the potential of ion chromatography (IC) while at International Plasma Corporation. In 1980, Smith-Kline acquired International Plasma Corporation. The IC division was spun off as a separate company, under the name Dionex Corporation, in a leveraged buyout (LBO) led by A. Blaine Bowman. Bowman became the president and CEO of the new company, which was incorporated in California in 1980. The company was reincorporated in Delaware in 1986. Dionex began to trade publicly as of 1982. Under Bowman's leadership, Dionex made important advances both scientifically and economically. The company directed up to nine percent of its revenues back into its ongoing research and development program.

Specifically, it binds to microtubule-associated proteins and/or to tubulin and produces depolymerization of microtubules (Kd = 10–20 μM for estramustine), resulting in the arrest of cell division in the G2/M phase (specifically metaphase). EMP was originally thought to mediate its cytostatic effects as a prodrug of normustine, a nitrogen mustard, and hence was thought to be an alkylating antineoplastic agent. However, subsequent research has found that EMP is devoid of alkylating actions, and that the influence of EMP on microtubules is mediated by intact estramustine and estromustine, with normustine or estradiol alone having only minor or negligible effects. As such, the unique properties of the estramustine and estromustine structures, containing a carbamate-ester bond, appear to be responsible for the cytostatic effects of EMP. In addition to its antimitotic actions, EMP has also been found to produce other cytostatic effects, including induction of apoptosis, interference with DNA synthesis, nuclear matrix interaction, cell membrane alterations, induction of reactive oxygen species (free oxygen radicals), and possibly additional mechanisms. EMP has been found to have a radiosensitizing effect in prostate cancer and glioma cells, improving sensitivity to radiation therapy as well. The cytostatic metabolites of EMP are accumulated in tissues in a selective manner, for instance in prostate cancer cells.

Numerous species of hagfish feed on carrion, including Atlantic hagfish, black hagfish, blueband hagfish, Pacific hagfish, slender hagfish and whiteface hagfish. Types of carrion eaten include dead whales, hake, mackerel, pilchards and jellyfish, as well as fishery discards of whiting and langoustine. Hagfish are highly adapted to carrion feeding. For example, they are able to survive extended periods without eating and can detect carrion from long distances. Hagfish are also highly mobile and can arrive at carcasses within minutes or hours of an animal’s death. Immune defenses such as lysozyme-containing slime and antimicrobial proteins (e.g. myxinidin) are thought to protect hagfish from microbial pathogens.

Sources: en.wikipedia.org

Notes from published material

Pre-preg allows one to impregnate the fibers on a flat workable surface, or rather in an industrial process, and then later form the impregnated fibers to a shape which could prove to be problematic for the hot injection process. Pre-preg also allows one to impregnate a bulk amount of fiber and then store it in a cooled area (below 20 °C) for an extended period of time to cure later. The process can also be time-consuming in comparison to the hot injection process and the added value for pre-preg preparation is at the stage of the material supplier.

Copyright infringement is the unauthorized or prohibited use of works under copyright, infringing the copyright holder's exclusive rights, such as the right to reproduce or perform the copyrighted work, or to make derivative works. Whilst almost universally considered under civil procedure, the impact and intent of organized criminal operations in this area of crime has been the subject of much debate. Article 61 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) requires that signatory countries establish criminal procedures and penalties in cases of willful trademark counterfeiting or copyright piracy on a commercial scale. More recently copyright holders have demanded that states provide criminal sanctions for all types of copyright infringement. Organized criminal groups capitalize on consumer complicity, advancements in security and anonymity technology, emerging markets and new methods of product transmission, and the consistent nature of these provides a stable financial basis for other areas of organized crime.

== Content == In the EDL, essential diagnostic tests are defined as those "that satisfy the priority health care needs of the population and are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness." The first edition contained 62 test categories and the second was updated to include 122 test categories. The categories of tests include: general laboratory tests and disease-specific tests such as for hepatitis B and C, HIV, HPV, malaria, syphilis and tuberculosis. The third edition added a "Do Not Do" recommendation, for tests deemed no longer useful. Some tests such as a quick test for malaria, do not require a laboratory, a health care setting or professional, or electricity. For each group of tests, the EDL specifies the test's name, purpose, assay format and type of specimen. Supporting WHO Guidelines or publications are linked and brands are not referenced. The EDL includes recommendations of types of tests that should be available in community settings where there are no laboratories, such as for anaemia, malaria or pregnancy. Laboratory tests such as those for testing for cancers are recommended for hospitals and laboratories.

== Research and career == Barran stayed with Stace for three years after completing her PhD in 1998. In 2001 Barran joined the University of California, Santa Barbara, working as a postdoctoral fellow with Mike Bowers. She was interested in the structure and stability of small molecules in the gas phase. She looked at how Ion-mobility spectrometry could be used to identify conformation. Barran joined the University of Edinburgh as an Engineering and Physical Sciences Research Council (EPSRC) Advanced Research Fellow in 2002. In 2005 she was awarded the 10th Desty Memorial prize for her innovations in Separation Science. She was made a Senior Lecturer in 2009. She worked on mass spectrometry techniques that can be used to evaluate conformational change, aggregation and intrinsic conformation. She investigated mass spectrometry for therapeutics for pre-fibrillar aggregation. She helped to establish the Scottish Instrumentation and Resource Centre for Advanced Mass Spectrometry at the University of Edinburgh. This had an initial remit to provide proteomic analysis for the MRC Human Genetics Unit. In 2013 Barran was appointed to the Manchester Institute of Biotechnology as a Chair in Mass Spectrometry sponsored by Waters Corporation. She led an EPSRC platform grant to study the structure-activity relationships of Beta defensins. She works with Cait MacPhee, Garth Cooper and Tilo Kunath on neurodegenerative proteins, and with several groups including Richard Kriwacki, Rohit Pappu and Gary Daughdrill to examine intrinsically disordered proteins.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Has it been approved for any medical use?

No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.

Which receptor matters most for pigmentation?

Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

Network